|
[1] SIMONNEAU G,GATZOULIS MA,ADATIA I,et al. Updated clinical classification of pulmonary hypertension[J]. J Am Coll Cardiol,2013,62(25 Suppl):34-41.
|
|
[2] MANTZ FA Jr,CRAIGE E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale[J]. AMA Arch Pathol,1951,52(1):91-97.
|
|
[3] BADESCH DB,RASKOB GE,ELLIOTT CG,et al. Pulmonary arterial hypertension:baseline characteristics from the REVEAL Registry[J]. Chest,2010,137(2):376-387.
|
|
[4] MANCUSO L,SCORDATO F,PIERI M,et al. Management of portopulmonary hypertension:new perspectives[J]. World J Gastroenterol,2013,19(45):8252-8257.
|
|
[5] RODRIGUEZ-ROISIN R,KROWKA MJ,HERVP,et al. Pulmonary-Hepatic vascular Disorders(PHD)[J]. Eur Respir J,2004,24(5):861-880.
|
|
[6] LI J,ZHUANG Q,ZHANG X,et al. Prevalence and prognosis of portopulmonary hypertension in 223 liver transplant recipients[J]. Can Respir J,2018,2018:1-6.
|
|
[7] KAWUT SM,KROWKA MJ,TROTTER JF,et al. Clinical risk factors for portopulmonary hypertension[J]. Hepatology,2008,48(1):196-203.
|
|
[8] RAMSAY MA,SIMPSON BR,NGUYEN AT,et al. Severe pulmonary hypertension in liver transplant candidates[J]. Liver Transpl Surg,1997,3(5):494-500.
|
|
[9] LE PJ,SOUZA R,HERVE P,et al. Portopulmonary hypertension:Survival and prognostic factors[J]. Am J Respir Crit Care Med,2008,178(6):637-643.
|
|
[10] SEGRAVES JM,CARTIN-CEBA R,LEISE MD,et al. Relationship between portopulmonary hypertension and splenectomy:Mayo Clinic experience and review of published works[J]. Hepatol Res,2018,48(3):340-346.
|
|
[11] RODRGUEZ-VILARRUPLA A,FERNNDEZ M,BOSCH J,et al. Current concepts on the pathophysiology of portal hypertension[J]. Ann Hepatol,2007,6(1):28-36.
|
|
[12] RAEVENS S,GEERTS A,van STEENKISTE C,et al. Hepatopulmonary syndrome and portopulmonary hypertension:Recent knowledge in pathogenesis and overview of clinical assessment[J]. Liver Int,2015,35(6):1646-1660.
|
|
[13] TALWALKAR JA,SWANSON KL,KROWKA MJ,et al. Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment[J].Gastroenterology,2011,141(5):1673-1679.
|
|
[14] THEVENOT T,WEIL D,di MARTINO V. What is the true relationship between spontaneous portosystemic shunts and portopulmonary hypertension in cirrhotic patients[J]. Gastroenterology,2018,155(5):1647-1648.
|
|
[15] LANE KB,MACHADO RD,PAUCIULO MW,et al. Heterozygous germline mutations in BMPR2,encoding a TGF-beta receptor,cause familial primary pulmonary hypertension[J].Nature Genetics,2000,26(1):81-84.
|
|
[16] DENG Z,MORSE JH,SLAGER SL,et al. Familial primary pulmonary hypertension(gene PPH1)is caused by mutations in the bone morphogenetic protein receptor-II gene[J]. Am J Hum Genet,2000,67(3):737-744.
|
|
[17] NIKOLIC I,YUNG LM,YANG P,et al. Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension[J]. Am J Respir Crit Care Med,2019,199(7):891-902.
|
|
[18] POUSADA G,BALOIRA A,VALVERDE D. Mutational screening in genes related with porto-pulmonary hypertension:An analysis of 6 cases[J]. Med Clin(Barc),2017,148(7):310-313.
|
|
[19] CHEN H,WANG F,XIAO J,et al. Natural killer cell-mediated immune deficiency or compromise in patients with portopulmonary hypertension[J]. Arch Med Sci,2014,10(5):1055-1056.
|
|
[20] ROBERTS KE,FALLON MB,KROWKA MJ,et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease[J]. Am J Respir Crit Care Med,2009,179(9):835-842.
|
|
[21] TERAO M,TAKAKI A,MARUYAMA T,et al. Serum oxidative/anti-oxidative stress balance is dysregulated in potentially pulmonary hypertensive patients with liver cirrhosis:A case control study[J]. Intern Med,2015,54(22):2815-2826.
|
|
[22] FUSSNER LA,IYER VN,CARTIN-CEBA R,et al. Intrapulmonary vascular dilatations are common in portopulmonary hypertension and may be associated with decreased survival[J].Liver Transpl,2015,21(11):1355-1364.
|
|
[23] SIMONNEAU G,MONTANI D,CELERMAJER DS,et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension[J]. Eur Respir J,2019,53(1):1801913.
|
|
[24] SWANSON KL,KROWKA MJ. Arterial oxygenation associated with porto-pulmonary hypertension[J]. Chest,2002,121(6):1869-1875.
|
|
[25] COLLE IO,MOREAU R,GODINHO E,et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation:a prospective study[J]. Hepatology,2003,37(2):401-409.
|
|
[26] KROWKA MJ,SWANSON KL,FRANTZ RP,et al. Portopulmonary hypertension:Results from a 10-year screening algorithm[J]. Hepatology,2006,44(6):1502–1510.
|
|
[27] DUBROCK HM,RODRIGUEZ-LOPEZ JM,LEVARGE BL,et al. Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension[J]. Pulm Circ,2016,6(4):498-507.
|
|
[28] LONG L,ORMISTON ML,YANG X,et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension[J]. Nat Med,2015,21(7):777-785.
|
|
[29] MIMIDIS KP,VASSILAKOS PI,MASTORAKOU AN,et al.Evaluation of contrast echocardiography and lung perfusion scan in detecting intrapulmonary vascular dilatation in normoxemic patients with early liver cirrhosis[J]. Hepatogastroenterology,1998,45(24):2303-2307.
|
|
[30] AWDISH RL,CAJIGAS HR. Early initiation of prostacyclin in portopulmonary hypertension:10 years of a transplant center’s experience[J]. Lung,2013,191(6):593-600.
|
|
[31] SITBON O,CHANNICK R,CHIN KM,et al. Selexipag for the treatment of pulmonary arterial hypertension[J]. N Engl J Med,2015,373(26):2522-2533.
|
|
[32] SIMONNEAU,GALIN,JANSA P,et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients[J]. Int J Cardiol,2014,172(2):332-339.
|
|
[33] CARTIN-CEBA R,SWANSON K,IYER V,et al. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension[J]. Chest,2011,139(1):109-114.
|
|
[34] PULIDO T,ADZERIKHO I,CHANNICK RN,et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension[J]. N Engl J Med,2013,369(9):809-818.
|
|
[35] SITBON O,BOSCH J,COTTREEL E,et al. Macitentan for the treatment of portopulmonary hypertension(PORTICO):A multicentre,randomised,double-blind,placebo-controlled,phase 4 trial[J]. Lancet Respir Med,2019,7(7):594-604.
|
|
[36] FISHER JH,JOHNSON SR,CHAU C,et al. Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension[J]. Can Respir J,2015,22(1):42-46.
|
|
[37] STEVELING E,OLSCHEWSKI H,GRIMMINGER F,et al. Sildenafil treatment for portopulmonary hypertension[J]. Eur Respir J,2006,28(3):563-567.
|
|
[38] CARTIN-CEBA R,HALANK M,GHOFRANI HA,et al. Riociguat treatment for portopulmonary hypertension:A subgroup analysis from the PATENT-1/-2 studies[J]. Pulm Circ,2018,8(2):2045894018769305.
|
|
[39] GHOFRANI HA,GRIMMINGER F,GRUNIG E,et al. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary arterial hypertension:Data from the PATENT-2 open-label,randomised,longterm extension trial[J]. Lancet Respir Med,2016,4(5):361-371.
|
|
[40] SCHWABL P,BRUSILOVSKAYA K,RIEDL F,et al. The guanylyl cyclase stimulator rloclguat reduces liver fibrosis and portal pressure in cirrhotic rats[J]. J Hepatology,2016,64(2):s140.
|
|
[41] VIONNET J,YERLY P,AUBERT JD,et al. Management of severe portopulmonary hypertension with dual oral therapy prior to liver transplantation[J]. Transplantation,2018,102(5):e194.
|
|
[42] VIONNET J,YERLY P,AUBERT JD,et al. Management of severe portopulmonary hypertension with dual oral therapy prior to liver transplantation[J]. Transplantation,2018,102(5):e194.
|
|
[43] LIU YJ,LI T. An excerpt of international liver transplant society practice guidelines:Diagnosis and management of hepatopulmonary hypertension(2016)[J]. J Clin Hepatol,2016,32(10):1838-1842.(in Chinese)刘以俊，李涛．《2016年国际肝移植学会实践指南:肝肺综合征与门脉性肺动脉高压的诊断与管理》摘译[J]．临床肝胆病杂志，2016,32(10):1838-1842.
|
|
[44] SARAGAI Y,TAKAKI A,UMEDA Y,et al. A subclinical high tricuspid regurgitation pressure gradient independent of the mean pulmonary artery pressure is a risk factor for the survival after living donor liver transplantation[J]. BMC Gastroenterol,2018,18(1):62.
|
|
[45] REYMOND M,BARBIER L,SALAME E,et al. Does portopulmonary hypertension impede liver transplantation in cirrhotic patients? A French multicentric retrospective study[J]. Transplantation,2018,102(4):616-622.
|
|
[46] GRANNAS G,NEIPP M,HOEPER MM,et al. Indications for and outcomes after combined lung and liver transplantation:A single-center experience on 13 consecutive cases[J].Transplantation,2008,85(4):524-531.
|
|
[47] ROBALINO BD,MOODIE DS. Association between primary pulmonary hypertension and portal hypertension:Analysis of its pathophysiology and clinical,laboratory and hemodynamic manifestations[J]. J Am Coll Cardiol,1991,17(2):492-498.
|
|
[48] LEPAVEC J,SOUZA R,HERVE P,et al. Portopulmonary hypertension:Survival and prognostic factors[J]. Am J Respir Crit Care Med,2008,178(6):637-643.
|
|
[49] KAWUT SM,TAICHMAN DB,AHYA VN,et al. Hemodynamics and survival of patients with porto-pulmonary hypertension[J]. Liver Transpl,2005,11(9):1107-1111.
|
|
[50] KROWKA MJ,MILLER DP,BARST RJ,et al. Portopulmonary hypertension:A report from the US-based REVEAL Registry[J]. Chest,2012,141(4):906-915.
|
|
[51] SWANSON KL,WIESNER RH,NYBERG SL,et al. Survival in porto-pulmonary hypertension:Mayo Clinic experience categorized by treatment subgroups[J]. Am J Transplant,2008,8(11):2445-2453.
|
DownLoad: